Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Upstream BioUPB +0.16%10 Cash Ratio is 21.55 as of Mar. 2026, which is 11% below its 10-year median of 24.21. GuruFocus rates UPB with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 1,384 Biotechnology companies, Upstream Bio ranks better than 94.22% on this metric.
Upstream Bio has a Cash Ratio of 21.55. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Upstream Bio's Cash Ratio or its related term are showing as below:
UPB'
s Cash Ratio Range Over the Past 10 Years
Min: 3.51 Med: 24.21 Max: 45.09
Current: 21.55
During the past 4 years, Upstream Bio's highest Cash Ratio was 45.09. The lowest was 3.51. And the median was 24.21.
UPB's Cash Ratio is ranked better than 94.22% of 1384
companies
in the Biotechnology industry
Industry Median: 2.94
vs UPB: 21.55
Upstream Bio (NAS:UPB) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Upstream Bio Cash Ratio Related Terms
Upstream Bio Cash Ratio Historical Data
* Premium members only.
The historical data trend for Upstream Bio's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Upstream Bio's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Upstream Bio Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Upstream Bio's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Upstream Bio's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Upstream Bio (UPB) has a Cash Ratio of 21.55 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Upstream Bio and its competitors. This is 11% below median its historical median of 24.21. Over the past decade, Upstream Bio's Cash Ratio has ranged from 3.51 to 45.09. According to the industry distribution chart, Upstream Bio ranks #80 out of 1384 companies in the Biotechnology industry, placing it in the top 5.8%.
Is Upstream Bio's Cash Ratio too high?
Upstream Bio's current Cash Ratio of 21.55 is 11% below median its 10-year median of 24.21. Over the past 10 years, this metric has ranged from a low of 3.51 to a high of 45.09. The Biotechnology industry median Cash Ratio is 2.94. Upstream Bio's value of 21.55 is 633% above this industry median. Based on the distribution chart, Upstream Bio ranks #80 out of 1384 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Upstream Bio has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Upstream Bio's Cash Ratio compare to OABI and VNDA?
According to the Biotechnology industry distribution chart, Upstream Bio ranks #80 out of 1384 companies for Cash Ratio. This places Upstream Bio in the top 6% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.94. Upstream Bio's value of 21.55 is 633% above this benchmark. Historically, Upstream Bio's own Cash Ratio has ranged from 3.51 to 45.09 over the past decade. While the company's 10-year median is 24.21 vs. the industry median of 2.94, Upstream Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.94, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Upstream Bio's current Cash Ratio of 21.55 is 633% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Upstream Bio and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Upstream Bio's current Cash Ratio is 21.55, which is 11% below median its own 10-year median of 24.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Upstream Bio stock overvalued right now?
Upstream Bio (UPB) has a current Cash Ratio of 21.55. The current Cash Ratio is 21.55, which is 11% below median its 10-year median of 24.21 and 633% above the Biotechnology industry median of 2.94. Upstream Bio's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Upstream Bio (UPB), the current Cash Ratio is 21.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
10GF Score
Get the complete analysis for UPB
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UPB has been successfully added to your 
